ReviewHealth science reports2026
Effectiveness and Safety of Pharmacological Therapy for Osteoporosis in Frail Elderly Individuals: Systematic Review and Meta-Analysis.
Review in Health science reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Frailty and osteoporosis are interrelated conditions that predominantly affect older adults. The greater the individual's frailty, the greater the probability of suffering a fracture and the greater the risk of fractures occurring in the future. Therefore, this study aimed to verify whether anti-fracture pharmacological therapies in frail individuals with osteoporosis are effective and safe. Methods: A systematic review of the literature was conducted using randomized clinical trials and observational studies. Participants aged 60 years or older, living in the community or in a long-term care facility, diagnosed with frailty and osteoporosis and with a history of anti-fracture medication use were evaluated. A meta-analysis was performed when appropriate. This review was conducted and reported following the PRISMA 2020 guidelines. Results: Six studies with 42,851 frail elderly were included. Five were conducted in long-term care facilities (3 observational and 2 randomized clinical trials) and 1 observational study included community-dwelling elderly after hospitalization due to fragility fracture. All studies assessed fractures; four evaluated mortality, and one assessed bone mineral density. Three studies compared bisphosphonates to a non-antiosteoporotic treatment; one compared bisphosphonate, denosumab, and teriparatide to placebo; one compared denosumab and zoledronic acid to teriparatide; and one compared sequential teriparatide with alendronate to alendronate. Meta-analysis pointed to a potential reduction in hip fracture risk and mortality with bisphosphonates in institutionalized frail elderly. It also demonstrated that bisphosphonates can be safe with limited nonserious side effects. Conclusion: The findings suggest a possible benefit of pharmacological treatment in reducing hip fractures and mortality in frail elderly. The real impact of the anti-fracture therapies on those individuals still needs to be better studied.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.